Media headlines about Nymox Pharmaceutical (NASDAQ:NYMX) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Nymox Pharmaceutical earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.9580984993737 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Nymox Pharmaceutical (NASDAQ:NYMX) traded up $0.10 during mid-day trading on Friday, hitting $3.39. The stock had a trading volume of 85,098 shares, compared to its average volume of 87,370. The firm has a market cap of $180.40, a PE ratio of -14.12 and a beta of 0.83. The company has a current ratio of 1.44, a quick ratio of 1.42 and a debt-to-equity ratio of 61.64. Nymox Pharmaceutical has a fifty-two week low of $2.80 and a fifty-two week high of $5.10.
COPYRIGHT VIOLATION NOTICE: “Nymox Pharmaceutical (NYMX) Getting Somewhat Favorable Press Coverage, Report Finds” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thelincolnianonline.com/2018/01/13/nymox-pharmaceutical-nymx-getting-somewhat-favorable-press-coverage-report-finds.html.
About Nymox Pharmaceutical
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.